Navigation Links
Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
Date:9/3/2009

SAN DIEGO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 10:30 a.m. Eastern Time at the Four Seasons Hotel in New York City.
  • Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 3:50 p.m. Eastern Time at the Four Seasons Hotel in Boston.
  • ThinkEquity's 6th Annual Growth Conference on Tuesday, September 15, 2009 at 10:30 a.m. Pacific Time at the St. Regis Hotel in San Francisco.
  • UBS Global Life Sciences Conference 2009 on Tuesday, September 22, 2009 at 1:00 p.m. Eastern Time at the Grand Hyatt New York in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
2. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
4. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
5. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
10. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
11. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... Cambridge Semantics , the ... that its Anzo Smart Data Lake has been named a KMWorld Trend-Setting ... that help organizations succeed in surpassing their knowledge management goals. KMWorld searches for ...
(Date:9/12/2017)... ... September 12, 2017 , ... PhysIQ, ... cloud-based platform for ambulatory patient monitoring and clinical trial support, earned DPharm Idol ... conference in Boston. , Launched in 2005, PhysIQ leverages artificial intelligence (AI) ...
(Date:9/12/2017)... CALIF. (PRWEB) , ... September 12, 2017 , ... It ... few months, it has been hot, hot, hot, as Lajollacooks4u has had a record-breaking ... , Guests came from far and wide to celebrate company outings, family get-togethers, ...
(Date:9/12/2017)... ... 12, 2017 , ... VetStem Biopharma, Inc. , announced that a major ... full license to that patent. This patent covers methods for isolating ... this stem cell with matrix materials, and incorporating the stem cells in an implant. ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):